Hanmi’s Amosartan First To Benefit From Korean Linkage System
This article was originally published in PharmAsia News
Hanmi Pharm's Amosartan combination drug has been selected as the first product whose generic versions will be given nine months of marketing exclusivity under Korea’s new patent-approval linkage system.
You may also be interested in...
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.